HCV antibody quantitative levels in liver transplant patients: Do they have any relevance in clinical practice?

Experimental and Clinical Transplantation

Volumn 4, Issue 1, 2006, Pages 475-480

  Jain, Ashok ^a   Menegus, Marilyn ^a   Mohanka, Ravi ^a   Orloff, Mark ^a   Abt, Peter ^a   Mantry, Parvez ^a   Bozorgzadeh, Adel ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antibody levels; Hepatitis C recurrence; Liver transplant

Indexed keywords

HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER INJURY; LIVER TRANSPLANTATION; MALE; NONHUMAN; QUANTITATIVE ASSAY; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; UNITED STATES; UNIVERSITY HOSPITAL; VIRUS LOAD;

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 33745621287     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10 (2): 199-207
2. Mukherjee S, Lyden E, McCashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20 (2): 198-203
3. Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004; 10 (5): 595-598
4. Bonino F, Brunetto MR, Negro F, Baldi M, Saracco G, Abate ML, et al. Hepatitis C virus infection and disease. Diagnostic problems. J Hepatol 1993; 17 Suppl 3: S78-S82
5. Charlton M, Wiesner R. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 2004; 24 Suppl 2: 79-88
6. Lopez-Labrador FX, Berenguer M, Sempere A, Prieto M, Sirera R, Gonzalez-Molina A, et al. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10 (2): 217-227.
7. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77 (2): 190-194
8. Yedibela S, Schuppan D, Muller V, Schellerer V, Tannapfel A, Hohenberger W, Meyer T. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation. Liver Int 2005; 25 (4): 717-722
9. Booth JC, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infections: predictive value of genotype and level of viremia on disease progression and response to interferon alpha. Gut 1995; 36 (3): 427-432
10. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23 (4): 695-699
11. Tassopoulos NC, Papatheodoridis GV, Katsoulidou A, Delladetsima JK, Sypsa V, Touloumi G, et al. Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology 1998; 45 (23): 1678-1683
12. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15 (4): 572-577
13. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24 (6): 1351-1354
14. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993; 104 (2): 595-603
15. Molmenti EP, Klintmalm GB. Hepatitis C recurrence after liver transplantation. Liver Transpl 2000; 6 (4): 413-414
16. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71 (8): 6011-6019
17. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995; 346 (8981): 1006-1007
18. Oethinger M, Mayo DR, Falcone J, Barua PK, Griffith BP. Efficiency of the ortho VITROS assay for detection of hepatitis C virus-specific antibodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios. J Clin Microbiol 2005; 43 (5): 2477-2480
19. Aoki SK, Kuramoto IK, Anderson S, Schoening V, Rodriguez R, Fernando L, et al. Evidence that use of a second-generation hepatitis C antibody assay prevents additional cases of transfusion-transmitted hepatitis. J Viral Hepat 1994; 1 (1): 73-77
20. Baath L, Widell A, Nordenfelt E. A comparison between one first generation and three second generation anti-HCV ELISAs: an investigation in high- and low-risk subjects in correlation with recombinant immunoblot assay and polymerase chain reaction. J Virol Methods 1992; 40 (3): 287-296
21. Leahy D, Kink J, Byrne R, Shah D, Preisel-Simmons B, Laska S, et al. Improved serologic detection of hepatitis C virus with a paramagnetic microparticle assay using multiple antigenic sequences. Transfusion 1992; 32 (6): 548-553
22. Lee S, McHutchinson J, Francis B, DiNello R, Polito A, Quan S, Nelles M. Improved detection of antibodies to hepatitis C virus using a second generation ELISA. Adv Exp Med Biol 1992; 312: 183-189
23. Mitchel LS, Jeffers LJ, Reddy KR, Cheinquer H, Coelho-Little E, Moreda R, et al. Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III. Am J Gastroenterol 1993; 88 (7): 1027-1034
24. Rowan BP, Smith A, Gleeson D, Hunt LP, Warnes TW. Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact? Gut 1994; 35 (4): 542-546
25. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91 (16): 7792-7796
26. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93 (26): 15394-15399
27. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11 (8): 941-949